Search results
Results from the WOW.Com Content Network
The rubella vaccine is a live attenuated vaccine. It is available either by itself or in combination with other vaccines. Combinations include with measles (MR vaccine), measles and mumps vaccine (MMR vaccine) and measles, mumps and varicella vaccine (MMRV vaccine). [1] A rubella vaccine was first licensed in 1969. [3]
Rubella virus (RuV) is the pathogenic agent of the disease rubella, transmitted only between humans via the respiratory route, and is the main cause of congenital ...
This page was last edited on 6 December 2023, at 11:03 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Rubella infections are prevented by active immunization programs using live attenuated virus vaccines. Two live attenuated virus vaccines, RA 27/3 and Cendehill strains, were effective in the prevention of adult disease. However, their use in prepubertal females did not produce a significant fall in the overall incidence rate of CRS in the UK.
For this there are two different vaccines, the MMR and the MMRV. The MMR protects against measles, mumps and rubella and is given in 2 doses between 12 and 15 months of age. The MMRV protects against measles, mumps, rubella and varicella. [48] Some side effects of the MMR vaccine are [2] fever (1 in 6) mild rash (1 in 20)
A variant of the rustrela virus-- related to the wider-known rubella virus which causes a skin rash in humans -- called RusV was discovered in a female mountain lion in Douglas County, Colorado ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 20 December 2024. Combined vaccine against measles, mumps, and rubella Pharmaceutical compound MMR vaccine MMR vaccine Combination of Measles vaccine Vaccine Mumps vaccine Vaccine Rubella vaccine Vaccine Clinical data Trade names M-M-R II, Priorix, Tresivac, others Other names MPR vaccine AHFS / Drugs ...
Measles & Rubella Initiative (MRI), launched in 2001, is a long-term commitment and partnership among leaders in public health and supports the goal of reducing measles deaths globally by 90% by 2010 compared to 2000 estimates.